Study: Heart problems, deaths linked to inhaler lung drugs
Inhaler lung drugs, including Boehringer Ingelheim's Spiriva Handihaler and Atrovent, may slightly elevate the risk of heart attacks and deaths, particularly in patients with chronic obstructive pulmonary disease, according to a U.S. study. A lung expert said more research needs to be done to determine what led to the increased risks because the treatments are not known to cause heart problems.
Washington Post, The | 09/23
This story published in FMI Pharmacy dailyLead on 09/24/2008
More from SmartBrief:
FDA panel supports bolder label for Spiriva Handihaler
Friday, November 20, 2009
FDA staff raises concern about risks tied to lung drug Spiriva
Wednesday, November 18, 2009
Studies: AstraZeneca, Boehringer drugs beat older blood thinners
Monday, August 31, 2009
Get stories like these delivered daily for FREE:
|
FMI Pharmacy dailyLead
Designed specifically for pharmacy professionals, FMI Pharmacy dailyLead is a FREE, daily e-mail newsletter. It provides the latest news in the pharmacy arena. Learn more |
|